-- Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype
-- Only biologic approved for oral corticosteroid-dependent asthma, regardless of phenotype
-- Only asthma biologic that offers patient self-administration at home
-- Only asthma biologic also approved for adult patients with moderate-to-severe atopic dermatitis, a Type 2 inflammatory disease driven by the IL-4 and IL-13 pathway
-- In clinical trials, Dupixent reduced severe exacerbations and oral corticosteroid use, and improved lung function
PR Newswire
PARIS and TARRYTOWN, N.Y., Oct. 19, 2018
